anti-Abeta monoclonal antibodies (Mapp Biopharmaceutical/Johns Hopkins University)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-Abeta monoclonal antibodies (Mapp Biopharmaceutical/Johns Hopkins University)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMapp Biopharmaceutical Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMapp Biopharmaceutical IncJohns Hopkins University
Active IndicationsN/A
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A